Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Nuclear factor of activated T-cells, NFATC1, governs FLT3ITD-driven hematopoietic stem cell transformation and a poor prognosis in AML

Fig. 3

Analysis of treatment sensitivity to quizartinib and chemotherapy. (a, b) Response to in vitro cytarabine treatment of total bone marrow. CFU number after treatment (a). Normalized CFU reduction (b). (mean ± SD. n = 3) 2-way ANOVA with Bonferroni multiple comparison was used for p values. c Scheme of in vivo treatment. d Histology of the bone marrow of AC220- and chemotherapy-treated groups. Scale bar, 100 μm. (eh) Normalized CFU number reduction (e), normalized bone marrow LSK reduction (f), normalized bone marrow LK reduction (g), normalized bone marrow Gr-1/CD11b+ reduction (h) (median ± IR. n = 6 to 10). Mann-Whitney test was used for p values. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page